Abstract
Short interfering RNA (siRNA), a small duplex of RNA fragment, has proved as an extremely useful research tool to interrogate gene functions in test tubes. However, the transformation of siRNAs from a functional genomic tool into a new therapeutic modality has been hindered by ineffective delivery methods for systemic administration. In this review, we will discuss the recent advances in formulating new delivery strategies that target siRNAs to specific cells following systemic administration. Special emphasis will be given to leukocytes, since siRNA delivery remains exceptionally challenging here due to the unavailability of effective delivery technologies. We will not only detail new platforms that utilize leukocyte integrins as receptor targets for siRNAs delivery, but also show how one of these strategies has been utilized for in vivo drug target validation of a novel anti-inflammatory target, cyclin D1, for inflammatory bowel diseases.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 853-859 |
| Number of pages | 7 |
| Journal | Cell Cycle |
| Volume | 8 |
| Issue number | 6 |
| DOIs | |
| State | Published - Mar 15 2009 |
Keywords
- Clinical trial
- Cyclin
- Drug delivery
- Gene silencing
- Integrin
- Nano-medicine
- Nanoparticles
- Small interfering RNA (siRNA)
ASJC Scopus subject areas
- Cell Biology
- Molecular Biology
- Developmental Biology